Montelukast

Tier B — Position early

Montelukast

Merck & Co Inc

Originator

1997

First approval

Expiry (public)

$5.96B ▲

Peak sales

Small molecule

Type

Targets：CYSLTR1

Brand：Kipres, Singulair

Indications (approved)：Allergic rhinitis, Asthma, Hypersensitivity reaction, Seasonal allergic rhinitis, Perennial allergic rhinitis, Exercise-induced asthma

Regional status

Approved

1998-02-20

Discontinued

2005-09-01

China

Approved

1999-10-29

Japan

Approved

2001-06-20

Factories producing this API1

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

1 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Montelukast?

Approved indications include: Allergic rhinitis, Asthma, Hypersensitivity reaction, Seasonal allergic rhinitis, Perennial allergic rhinitis, Exercise-induced asthma.

When does the Montelukast patent expire?

No public expiry year is available for Montelukast yet; this page updates once verified.

How do I get a quote for Montelukast intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27